Free Trial

Tilray Brands (TSE:TLRY) Trading Down 2.9% - What's Next?

Tilray Brands logo with Medical background

Tilray Brands, Inc. (TSE:TLRY - Get Free Report) was down 2.9% on Friday . The company traded as low as C$0.67 and last traded at C$0.67. Approximately 696,847 shares traded hands during mid-day trading, a decline of 56% from the average daily volume of 1,587,825 shares. The stock had previously closed at C$0.69.

Tilray Brands Trading Up 14.5%

The firm has a 50 day moving average of C$0.60 and a 200-day moving average of C$1.02. The firm has a market capitalization of C$509.05 million, a P/E ratio of -1.91 and a beta of 2.19. The company has a quick ratio of 2.16, a current ratio of 2.54 and a debt-to-equity ratio of 10.76.

About Tilray Brands

(Get Free Report)

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. U.S. exposure consists of CBD products through Manitoba Harvest and beer through SweetWater.

Read More

Should You Invest $1,000 in Tilray Brands Right Now?

Before you consider Tilray Brands, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray Brands wasn't on the list.

While Tilray Brands currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines